Fungus beware: Cidara Therapeutics files for a $69 million IPO

(Renaissance Capital) Cidara Therapeutics, which is developing novel therapies for fungal infections, filed on Friday with the SEC to raise up to $69 million in an initial public offering. Last year's antifungal biotech SCYNEXIS (SCYX) trades at about its offer price. The San Diego, CA-based company, which was founded in 2012, plans to list on the NASDAQ under the symbol CDTX. Cidara Therapeutics initially filed confidentially on February 4, 2015. Jefferies and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.

Keywords / Tickers: Stock Market Trade Types, CDTX, SCYX

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.